Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Withings
HQ France · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jun 2026: Withings acquired Biosency, a French developer of remote monitoring for chronic respiratory disease, entering respiratory remote monitoring; the Biosency team joined Withings. No adverse media found.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Withings found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, FDA warning letters or safety notices involving Withings found in HSH's search of the last 24 months.
Contract performance
Jul 2026: Withings Medical launched a clinical care service. No notable NHS contracts, disputes or terminations involving Withings found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.